+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin drug use is not associated with prostate cancer risk in men who are regularly screened

Statin drug use is not associated with prostate cancer risk in men who are regularly screened

Journal of Urology 192(2): 379-384

Prospective cohort studies support the hypothesis that statin drug users have a lower risk of aggressive prostate cancer. Whether statin drug use influences the risk of screen detected disease is less clear, possibly because of complex detection biases. Thus, we investigated this association in a setting in which men had low baseline serum prostate specific antigen concentration and were screened annually. We performed a cohort study of 9,457 men 55 years old or older at randomization to the placebo arm of PCPT (Prostate Cancer Prevention Trial). The men reported new use of medications quarterly. We estimated the multivariable adjusted HR of prostate cancer (574 cases in 62,192 person-years) for statin drug use and duration of use during the trial using Cox proportional hazards regression. During 7 years of followup statin drug use during the trial was not associated with the risk of total prostate cancer (HR 1.03, 95% CI 0.82-1.30), or lower grade (HR 0.96, 95% CI 0.71-1.29) or higher grade (HR 1.27, 95% CI 0.85-1.90) prostate cancer. Duration of use during followup was also not associated with the risk of total, or lower or higher grade disease (p trend=0.7, 0.5 and 0.2, respectively). These prospective results do not support the hypothesis that statin drugs protect against prostate cancer in the setting of regular prostate cancer screening.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911070

Download citation: RISBibTeXText

PMID: 24518774

DOI: 10.1016/j.juro.2014.01.095

Related references

Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. Journal of Urology 183(2): 529-533, 2010

Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. Cancer Epidemiology 35(4): E6-11, 2012

Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. European Urology 58(4): 551-558, 2011

Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prevention Research 2(3): 244-250, 2009

Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. Urology 82(6): 1211-1217, 2014

Statin Use and Risk of Prostate Cancer in MrOS. 2012

Statin use and the risk of breast and prostate cancer. Epidemiology 13(3): 262-267, 2002

Statin and NSAID use and prostate cancer risk. Pharmacoepidemiology and Drug Safety 19(7): 752-755, 2010

The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. Journal of Medical Screening 18(4): 210-212, 2012

Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute 98(24): 1819-1825, 2006

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68(6): 1152-1155, 2006

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. Journal of Clinical Oncology 28(16): 2651-2652, 2010

Statin use and risk of prostate cancer in a population of men who underwent biopsy. Journal of Urology 186(1): 86-90, 2011

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz. 2007

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. European Journal of Cancer 51(6): 725-733, 2015